Has Cobalis been in contact with the FDA to scrupulously verify the procedures they need to follow to make the data acceptable for submission to the FDA after it has been corrected?
Or if this submission of corrected data to the FDA is even a possibility?
I'm wondering if it is possible because the data has already been unblinded, meaning that efforts to extract the correct data could be intentionally or unintentionally influenced by the knowledge of whether that patient was on Prehistin or Placebo.
Market Data 
Markets 
AI
